Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 738391, 9 pages
http://dx.doi.org/10.1155/2013/738391
Research Article

Qi-Shen-Yi-Qi Dripping Pills for the Secondary Prevention of Myocardial Infarction: A Randomised Clinical Trial

1Tianjin University of Traditional Chinese Medicine, 312 Anshanxi Road, Nankai District, Tianjin 300193, China
2Peking University First Hospital, Beijing 100034, China
3Chinese Academy of Traditional Chinese Medicine, Beijing 100700, China
4Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250011, China
5Xiyuan Hospital, Beijing 100091, China

Received 20 March 2013; Accepted 25 May 2013

Academic Editor: Hao Xu

Copyright © 2013 Hongcai Shang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, “The top ten causes of death,” Fact sheet, no. 310, 2008.
  2. H. D. White and D. P. Chew, “Acute myocardial infarction,” The Lancet, vol. 372, no. 9638, pp. 570–584, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. He, D. Gu, X. Wu et al., “Major causes of death among men and women in China,” New England Journal of Medicine, vol. 353, no. 11, pp. 1124–1134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Sanderson, B. Mayosi, S. Yusuf et al., “Global burden of cardiovascular disease,” Heart, vol. 93, no. 10, p. 1175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Moher, “Evidence of the effectiveness of interventions for secondary prevention and treatment of coronary heart disease in primary care—a review of the literature,” NHS Executive, Anglia and Oxford Regional Health Authority, Oxford, UK, 1995.
  6. Y.-Z. Xiang, Y. Xia, X.-M. Gao, H.-C. Shang, L.-Y. Kang, and B.-L. Zhang, “Platelet activation, and antiplatelet targets and agents: current and novel strategies,” Drugs, vol. 68, no. 12, pp. 1647–1664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Baigent, C. Sudlow, R. Collins, and R. Peto, “Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients,” British Medical Journal, vol. 324, no. 7329, pp. 71–86, 2002. View at Google Scholar · View at Scopus
  8. Antithrombotic Trialists' Collaboration, “Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials,” The Lancet, vol. 373, no. 9678, pp. 1849–1860, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. L. A. García Rodríguez, S. Hernández-Díaz, and F. J. de Abajo, “Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies,” British Journal of Clinical Pharmacology, vol. 52, pp. 563–571, 2001. View at Google Scholar
  10. S. Derry and Y. K. Loke, “Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis,” British Medical Journal, vol. 321, no. 7270, pp. 1183–1187, 2000. View at Google Scholar · View at Scopus
  11. G. De Berardis, G. Lucisano, A. D'Ettorre et al., “Association of aspirin use with major bleeding in patients with and without diabetes,” Journal of the American Medical Association, vol. 307, no. 21, pp. 2286–2294, 2012. View at Google Scholar
  12. M. M. C. Hovens, J. D. Snoep, J. C. J. Eikenboom, J. G. van der Bom, B. J. A. Mertens, and M. V. Huisman, “Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review,” American Heart Journal, vol. 153, no. 2, pp. 175–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. D. Snoep, M. M. C. Hovens, J. C. J. Eikenboom, J. G. Van Der Bom, and M. V. Huisman, “Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis,” Archives of Internal Medicine, vol. 167, no. 15, pp. 1593–1599, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Krasopoulos, S. J. Brister, W. S. Beattie, and M. R. Buchanan, “Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis,” British Medical Journal, vol. 336, no. 7637, pp. 195–198, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-Z. Xiang, L.-Y. Kang, X.-M. Gao, H.-C. Shang, J.-H. Zhang, and B.-L. Zhang, “Strategies for antiplatelet targets and agents,” Thrombosis Research, vol. 123, no. 1, pp. 35–49, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Yunfei, Q. Haibin, and C. Yiyu, “Identification of major constituents in the traditional Chinese medicine “QI-SHEN-YI-QI” dropping pill by high-performance liquid chromatography coupled with diode array detection-electrospray ionization tandem mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 47, no. 2, pp. 407–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Wang, J. Wang, L. Guo, and X. Gao, “Antiplatelet effects of qishen yiqi dropping pill in platelets aggregation in hyperlipidemic rabbits,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 205451, 5 pages, 2012. View at Publisher · View at Google Scholar
  18. J. Chen, D. Z. Qu, and R. Y. Wang, “Evaluation of Qishenyiqi Dripping Pills for aspirin resistance in patients with coronary heart disease,” Chinese Traditional and Herbal Drugs, vol. 39, pp. 96–97, 2008. View at Google Scholar
  19. J. S. Alpert, K. Thygesen, E. Antman, and J. P. Bassand, “Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction,” Journal of the American College of Cardiology, vol. 36, pp. 959–969, 2000. View at Google Scholar · View at Scopus
  20. Y. Z. Xiang, H. C. Shang, and B. L. Zhang, “Secondary prevention of myocardial infarction and applicable prospect of traditional Chinese medicine,” Medical Recapitulate, vol. 13, pp. 263–265, 2007. View at Google Scholar
  21. G. Sanz, V. Fuster, M.-J. Kravis, H. R. Kravis, and R. Gorlin, “Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population,” Nature Clinical Practice Cardiovascular Medicine, vol. 6, no. 2, pp. 101–110, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. J. Wald and M. R. Law, “The Indian Polycap Study (TIPS),” The Lancet, vol. 374, p. 781, 2009. View at Google Scholar
  23. N. J. Wald and M. R. Law, “A strategy to reduce cardiovascular disease by more than 80%,” British Medical Journal, vol. 326, no. 7404, pp. 1419–1423, 2003. View at Google Scholar · View at Scopus
  24. S. Yusuf, P. Pais, R. Afzal et al., “Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial,” The Lancet, vol. 373, pp. 1341–1351, 2009. View at Google Scholar
  25. E. Z. Soliman, S. Mendis, W. P. Dissanayake et al., “A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization,” Trials, vol. 12, article 3, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Gu, G. Yuan, Y. Zhu, and X. Xu, “Computational pharmacological studies on cardiovascular disease by Qishenyiqi Diwan,” Science in China B, vol. 39, pp. 1415–1423, 2009. View at Google Scholar
  27. S. Q. Lin, X. H. Wei, P. Huang, Y. Y. Liu et al., “QiShenYiQi Pills prevents cardiac ischemia-reperfusion injury via energy modulation,” International Journal of Cardiology, 2012. View at Publisher · View at Google Scholar
  28. C. Hong, Y. Wang, J. Lou, Q. Liu, H. Qu, and Y. Cheng, “Analysis of myocardial proteomic alteration after Qishenyiqi formula treatment in acute infarcted rat hearts,” Zhongguo Zhongyao Zazhi, vol. 34, no. 8, pp. 1018–1021, 2009. View at Google Scholar · View at Scopus
  29. W. X. Du, M. D. Zhu, L. M. Feng et al., “Intervention effect of Qishenyiqi dripping pills on early ventricular remodeling after acute myocardial infarction,” Chinese Journal of Evidence-Based Cardiovascular Medicine, vol. 28, pp. 41–43, 2008. View at Google Scholar
  30. F. F. Yan, Y. Liu, Y. F. Liu, and Y. X. Zhao, “Effects of Qishenyiqi Dripping pills on high sensitivity C reactive protein in experimental atherosclerosis rabbits,” Shanghai Journal of Traditional Chinese Medicine, vol. 41, pp. 59–60, 2007. View at Google Scholar
  31. F. F. Yan, Y. Liu, Y. F. Liu, and Y. X. Zhao, “Effect of Qishenyiqi dripping pills on histology of experimental atherosclerotic plaque,” Journal of Nanjing University of Traditional Chinese Medicine, vol. 23, pp. 295–297, 2007. View at Google Scholar